본문

서브메뉴

Controlled Release of a Mast Cell Agonist for Glioblastoma Immunotherapy
Controlled Release of a Mast Cell Agonist for Glioblastoma Immunotherapy
Controlled Release of a Mast Cell Agonist for Glioblastoma Immunotherapy

상세정보

자료유형  
 학위논문 서양
최종처리일시  
20260202105258
ISBN  
9798270297251
DDC  
615
저자명  
Mendell, Sophie Evelyn.
서명/저자  
Controlled Release of a Mast Cell Agonist for Glioblastoma Immunotherapy
발행사항  
[Sl] : The University of North Carolina at Chapel Hill, 2025
발행사항  
Ann Arbor : ProQuest Dissertations & Theses, 2025
형태사항  
96 p
주기사항  
Source: Dissertations Abstracts International, Volume: 87-07, Section: B.
주기사항  
Advisor: Ainslie, Kristy.
학위논문주기  
Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2025.
초록/해제  
요약Glioblastoma (GBM) is a devastating illness that claims the lives of nearly a quarter of a million people annually. The aggressive and immunologically complex nature of GBM, as well as its location behind the blood-brain barrier, restricts the efficacy of many cutting-edge therapies. While new immunotherapeutic strategies have made significant advances for certain patient subsets, there is a critical and unmet need for better treatments. One emerging player in the tumor microenvironment (TME) is the mast cell. A granulocyte of the innate immune system, the mast cell has established pro- and anti-tumor functions across many cancers, with emerging evidence for a role in GBM.Herein we establish MCs as an overrepresented population within two immunocompetent murine GBM models, when compared to healthy controls. We further identify the effects a GBM standard-of-care treatment (SOC), resection, has on MC populations. We identify and characterize a 2nd generation MC agonist, MP12W, for its in vitro safety profile, comparing MP12W to known MC activators, including another well-studied 2nd generation agonist and a standard degranulating control. Next, we produced two scaffolds for the interstitial delivery of a MC-agonist in GBM using the acetalated-dextran (Ace-DEX) controlled release platform. These scaffolds were then investigated for their effects on survival and MC phenotypes in two models of murine GBM. We observed successful in vivo MC activation but no tumor control in either model. To understand the mechanism of treatment failure, we completed multi-organ immunophenotyping of the T-cell and myeloid compartments. Our results show that MC agonism in GBM elicits broad immunosuppression. Further, when this agonism is sustained, as is achieved with Ace-DEX scaffolds, we observed increased exhausted CD4 T-cells. Altogether this work establishes MCs as an elevated immune population in GBM impacted by the SOC. Local delivery of a MC agonist impacts regional MC populations, but encapsulation of the agonist within an Ace-DEX scaffold results in phenotypic changes in systemic MC populations. However, we identify that activation of MCs in GBM dampens local and systemic immune populations. Our work further suggests that sustained MC agonism may push key populations within the TME to adopt classic pro-tumor phenotypes.
일반주제명  
Pharmaceutical sciences
일반주제명  
Cellular biology
일반주제명  
Molecular biology
일반주제명  
Immunology
키워드  
Glioblastoma
키워드  
Tumor microenvironment
키워드  
Standard-of-care treatment
키워드  
Acetalated-dextran
키워드  
Immunotherapy
기타저자  
The University of North Carolina at Chapel Hill Pharmaceutical Sciences
기본자료저록  
Dissertations Abstracts International. 87-07B.
전자적 위치 및 접속  
로그인 후 원문을 볼 수 있습니다.

MARC

 008260126s2025        us                              c    eng  d
■001000017360063
■00520260202105258
■006m          o    d                
■007cr#unu||||||||
■020    ▼a9798270297251
■035    ▼a(MiAaPQ)AAI32280076
■040    ▼aMiAaPQ▼cMiAaPQ
■0820  ▼a615
■1001  ▼aMendell,  Sophie  Evelyn.
■24510▼aControlled  Release  of  a  Mast  Cell  Agonist  for  Glioblastoma  Immunotherapy
■260    ▼a[Sl]▼bThe  University  of  North  Carolina  at  Chapel  Hill▼c2025
■260  1▼aAnn  Arbor▼bProQuest  Dissertations  &  Theses▼c2025
■300    ▼a96  p
■500    ▼aSource:  Dissertations  Abstracts  International,  Volume:  87-07,  Section:  B.
■500    ▼aAdvisor:  Ainslie,  Kristy.
■5021  ▼aThesis  (Ph.D.)--The  University  of  North  Carolina  at  Chapel  Hill,  2025.
■520    ▼aGlioblastoma  (GBM)  is  a  devastating  illness  that  claims  the  lives  of  nearly  a  quarter  of  a  million  people  annually.  The  aggressive  and  immunologically  complex  nature  of  GBM,  as  well  as  its  location  behind  the  blood-brain  barrier,  restricts  the  efficacy  of  many  cutting-edge  therapies.  While  new  immunotherapeutic  strategies  have  made  significant  advances  for  certain  patient  subsets,  there  is  a  critical  and  unmet  need  for  better  treatments.  One  emerging  player  in  the  tumor  microenvironment  (TME)  is  the  mast  cell.  A  granulocyte  of  the  innate  immune  system,  the  mast  cell  has  established  pro-  and  anti-tumor  functions  across  many  cancers,  with  emerging  evidence  for  a  role  in  GBM.Herein  we  establish  MCs  as  an  overrepresented  population  within  two  immunocompetent  murine  GBM  models,  when  compared  to  healthy  controls.  We  further  identify  the  effects  a  GBM  standard-of-care  treatment  (SOC),  resection,  has  on  MC  populations.  We  identify  and  characterize  a  2nd  generation  MC  agonist,  MP12W,  for  its  in  vitro  safety  profile,  comparing  MP12W  to  known  MC  activators,  including  another  well-studied  2nd  generation  agonist  and  a  standard  degranulating  control.  Next,  we  produced  two  scaffolds  for  the  interstitial  delivery  of  a  MC-agonist  in  GBM  using  the  acetalated-dextran  (Ace-DEX)  controlled  release  platform.  These  scaffolds  were  then  investigated  for  their  effects  on  survival  and  MC  phenotypes  in  two  models  of  murine  GBM.  We  observed  successful  in  vivo  MC  activation  but  no  tumor  control  in  either  model.  To  understand  the  mechanism  of  treatment  failure,  we  completed  multi-organ  immunophenotyping  of  the  T-cell  and  myeloid  compartments.  Our  results  show  that  MC  agonism  in  GBM  elicits  broad  immunosuppression.  Further,  when  this  agonism  is  sustained,  as  is  achieved  with  Ace-DEX  scaffolds,  we  observed  increased  exhausted  CD4  T-cells.  Altogether  this  work  establishes  MCs  as  an  elevated  immune  population  in  GBM  impacted  by  the  SOC.  Local  delivery  of  a  MC  agonist  impacts  regional  MC  populations,  but  encapsulation  of  the  agonist  within  an  Ace-DEX  scaffold  results  in  phenotypic  changes  in  systemic  MC  populations.  However,  we  identify  that  activation  of  MCs  in  GBM  dampens  local  and  systemic  immune  populations.  Our  work  further  suggests  that  sustained  MC  agonism  may  push  key  populations  within  the  TME  to  adopt  classic  pro-tumor  phenotypes.
■590    ▼aSchool  code:  0153.
■650  4▼aPharmaceutical  sciences
■650  4▼aCellular  biology
■650  4▼aMolecular  biology
■650  4▼aImmunology
■653    ▼aGlioblastoma
■653    ▼aTumor  microenvironment
■653    ▼aStandard-of-care  treatment
■653    ▼aAcetalated-dextran
■653    ▼aImmunotherapy
■690    ▼a0572
■690    ▼a0379
■690    ▼a0982
■690    ▼a0307
■71020▼aThe  University  of  North  Carolina  at  Chapel  Hill▼bPharmaceutical  Sciences.
■7730  ▼tDissertations  Abstracts  International▼g87-07B.
■790    ▼a0153
■791    ▼aPh.D.
■792    ▼a2025
■793    ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17360063▼nKERIS▼z이  자료의  원문은  한국교육학술정보원에서  제공합니다.

미리보기

내보내기

chatGPT토론

Ai 추천 관련 도서


    신착도서 더보기
    최근 3년간 통계입니다.

    소장정보

    • 예약
    • 소재불명신고
    • 나의폴더
    • 우선정리요청
    • 비도서대출신청
    • 야간 도서대출신청
    소장자료
    등록번호 청구기호 소장처 대출가능여부 대출정보
    TF16292 전자도서 대출가능 마이폴더 부재도서신고 비도서대출신청 야간 도서대출신청

    * 대출중인 자료에 한하여 예약이 가능합니다. 예약을 원하시면 예약버튼을 클릭하십시오.

    해당 도서를 다른 이용자가 함께 대출한 도서

    관련 인기도서

    로그인 후 이용 가능합니다.